1-(4-hydroxyphenyl)-3-(3-methoxyphenyl)thiourea is a specific compound with a complex chemical structure. It is a **thiourea derivative**, meaning it contains a thiourea functional group (NHCSNH2) attached to other aromatic rings.
**Why it's important for research:**
There isn't a lot of information available specifically about 1-(4-hydroxyphenyl)-3-(3-methoxyphenyl)thiourea, so it's difficult to say why it might be important for research without additional context.
However, thiourea derivatives are known to have a wide range of biological activities, including:
* **Antibacterial:** Some thiourea derivatives have been found to exhibit antibacterial activity against a variety of bacteria.
* **Antifungal:** Others have shown antifungal properties.
* **Antioxidant:** Thiourea derivatives can act as antioxidants, protecting cells from damage caused by free radicals.
* **Anti-inflammatory:** Some thiourea derivatives have been shown to have anti-inflammatory effects.
* **Enzyme inhibition:** Thioureas can interact with enzymes and inhibit their activity.
It's possible that 1-(4-hydroxyphenyl)-3-(3-methoxyphenyl)thiourea might be of interest to researchers studying these areas.
**To understand its specific importance, you would need more information about the research context:**
* **What is the research question?** What are the researchers trying to achieve?
* **What are the properties of this specific compound?** What are its chemical and physical properties?
* **How is it being used in the research?** Is it being used as a drug candidate, a probe, or a reagent?
Without this information, it's difficult to say why 1-(4-hydroxyphenyl)-3-(3-methoxyphenyl)thiourea is specifically important.
| ID Source | ID |
|---|---|
| PubMed CID | 2803091 |
| CHEMBL ID | 1597646 |
| CHEBI ID | 109437 |
| SCHEMBL ID | 17071992 |
| Synonym |
|---|
| mls000756446 , |
| nsc201634 |
| nsc-201634 |
| DIVK1C_001284 |
| CDS1_000244 |
| OPREA1_868650 |
| smr000528738 |
| MAYBRIDGE1_002532 |
| CHEBI:109437 |
| 1-(4-hydroxyphenyl)-3-(3-methoxyphenyl)thiourea |
| HMS548L02 |
| HMS2875L07 |
| CHEMBL1597646 , |
| Q27188568 |
| SCHEMBL17071992 |
| bdbm50235861 |
| Class | Description |
|---|---|
| thioureas | Compounds of general formula RR'NC(=S)NR''R'''. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Chain A, Putative fructose-1,6-bisphosphate aldolase | Giardia intestinalis | Potency | 17.7407 | 0.1409 | 11.1940 | 39.8107 | AID2451 |
| Luciferase | Photinus pyralis (common eastern firefly) | Potency | 30.1313 | 0.0072 | 15.7588 | 89.3584 | AID588342 |
| phosphopantetheinyl transferase | Bacillus subtilis | Potency | 19.9526 | 0.1413 | 37.9142 | 100.0000 | AID1490 |
| ATAD5 protein, partial | Homo sapiens (human) | Potency | 29.0810 | 0.0041 | 10.8903 | 31.5287 | AID504467 |
| USP1 protein, partial | Homo sapiens (human) | Potency | 35.4813 | 0.0316 | 37.5844 | 354.8130 | AID743255 |
| Microtubule-associated protein tau | Homo sapiens (human) | Potency | 17.7828 | 0.1800 | 13.5574 | 39.8107 | AID1460; AID1468 |
| thioredoxin glutathione reductase | Schistosoma mansoni | Potency | 56.2341 | 0.1000 | 22.9075 | 100.0000 | AID485364 |
| glucocerebrosidase | Homo sapiens (human) | Potency | 10.0000 | 0.0126 | 8.1569 | 44.6684 | AID2101 |
| bromodomain adjacent to zinc finger domain 2B | Homo sapiens (human) | Potency | 70.7946 | 0.7079 | 36.9043 | 89.1251 | AID504333 |
| euchromatic histone-lysine N-methyltransferase 2 | Homo sapiens (human) | Potency | 8.9125 | 0.0355 | 20.9770 | 89.1251 | AID504332 |
| serine/threonine-protein kinase PLK1 | Homo sapiens (human) | Potency | 21.1923 | 0.1683 | 16.4040 | 67.0158 | AID720504 |
| urokinase-type plasminogen activator precursor | Mus musculus (house mouse) | Potency | 3.5481 | 0.1585 | 5.2879 | 12.5893 | AID540303 |
| plasminogen precursor | Mus musculus (house mouse) | Potency | 3.5481 | 0.1585 | 5.2879 | 12.5893 | AID540303 |
| urokinase plasminogen activator surface receptor precursor | Mus musculus (house mouse) | Potency | 3.5481 | 0.1585 | 5.2879 | 12.5893 | AID540303 |
| ATP-dependent phosphofructokinase | Trypanosoma brucei brucei TREU927 | Potency | 20.1714 | 0.0601 | 10.7453 | 37.9330 | AID485367; AID504636 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Indoleamine 2,3-dioxygenase 1 | Homo sapiens (human) | IC50 (µMol) | 195.8500 | 0.0537 | 3.0757 | 10.0000 | AID1440267; AID1440271 |
| large T antigen | Betapolyomavirus macacae | IC50 (µMol) | 5.6400 | 0.1600 | 24.9724 | 100.0000 | AID1903 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Myocilin | Homo sapiens (human) | Kd | 0.0000 | 0.0000 | 0.0495 | 0.0990 | AID1488869 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| electron transfer activity | Indoleamine 2,3-dioxygenase 1 | Homo sapiens (human) |
| heme binding | Indoleamine 2,3-dioxygenase 1 | Homo sapiens (human) |
| indoleamine 2,3-dioxygenase activity | Indoleamine 2,3-dioxygenase 1 | Homo sapiens (human) |
| metal ion binding | Indoleamine 2,3-dioxygenase 1 | Homo sapiens (human) |
| tryptophan 2,3-dioxygenase activity | Indoleamine 2,3-dioxygenase 1 | Homo sapiens (human) |
| fibronectin binding | Myocilin | Homo sapiens (human) |
| frizzled binding | Myocilin | Homo sapiens (human) |
| protein binding | Myocilin | Homo sapiens (human) |
| receptor tyrosine kinase binding | Myocilin | Homo sapiens (human) |
| myosin light chain binding | Myocilin | Homo sapiens (human) |
| metal ion binding | Myocilin | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID1488870 | Binding affinity myocilin-OLF domain (unknown origin) assessed as change in melting temperature by Sypro Orange dye-based DSF assay | 2017 | Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17 | Pocket detection and interaction-weighted ligand-similarity search yields novel high-affinity binders for Myocilin-OLF, a protein implicated in glaucoma. |
| AID1440270 | Inhibition of recombinant human IDO1 S167A mutant expressed in Escherichia coli SG13009(pREP4) at 20 uM using L-Tryptophan as substrate after 25 mins by fluorescence assay relative to control | 2017 | European journal of medicinal chemistry, Jan-27, Volume: 126 | Discovery and evaluation of inhibitors to the immunosuppressive enzyme indoleamine 2,3-dioxygenase 1 (IDO1): Probing the active site-inhibitor interactions. |
| AID1440267 | Inhibition of recombinant human IDO1 expressed in bacterial expression system using L-Tryptophan as substrate after 25 mins in absence of GSH and presence of tween20 by fluorescence assay | 2017 | European journal of medicinal chemistry, Jan-27, Volume: 126 | Discovery and evaluation of inhibitors to the immunosuppressive enzyme indoleamine 2,3-dioxygenase 1 (IDO1): Probing the active site-inhibitor interactions. |
| AID1440268 | Inhibition of recombinant human IDO1 expressed in bacterial expression system at 20 uM using L-Tryptophan as substrate after 25 mins by fluorescence assay relative to control | 2017 | European journal of medicinal chemistry, Jan-27, Volume: 126 | Discovery and evaluation of inhibitors to the immunosuppressive enzyme indoleamine 2,3-dioxygenase 1 (IDO1): Probing the active site-inhibitor interactions. |
| AID1440272 | Selectivity ratio of IC50 for recombinant human IDO1 S167A mutant expressed in Escherichia coli SG13009(pREP4) to IC50 for recombinant human IDO1 expressed in bacterial expression system | 2017 | European journal of medicinal chemistry, Jan-27, Volume: 126 | Discovery and evaluation of inhibitors to the immunosuppressive enzyme indoleamine 2,3-dioxygenase 1 (IDO1): Probing the active site-inhibitor interactions. |
| AID1440271 | Inhibition of recombinant human IDO1 S167A mutant expressed in Escherichia coli SG13009(pREP4) using L-Tryptophan as substrate after 25 mins by fluorescence assay | 2017 | European journal of medicinal chemistry, Jan-27, Volume: 126 | Discovery and evaluation of inhibitors to the immunosuppressive enzyme indoleamine 2,3-dioxygenase 1 (IDO1): Probing the active site-inhibitor interactions. |
| AID1488869 | Binding affinity myocilin-OLF domain (unknown origin) by Sypro Orange dye-based DSF assay | 2017 | Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17 | Pocket detection and interaction-weighted ligand-similarity search yields novel high-affinity binders for Myocilin-OLF, a protein implicated in glaucoma. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 5 (71.43) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.29) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 7 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||